Los Angeles Capital Management
DMAC icon

Los Angeles Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Los Angeles Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,990
Closed -$161K – 2450
2025
Q4 		$161K Buy
+22,990
New +$172K ﹤0.01% 1305

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Los Angeles Capital Management's DMAC Position: Q1 2026 in Review

Los Angeles Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 22,990 shares — an estimated $161K sold.

Los Angeles Capital Management first reported a position in DMAC in Q4 2025 and held it in 1 quarter. The position peaked at $161K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Los Angeles Capital Management reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 22,990 DiaMedica Therapeutics shares in Q1 2026, an estimated $161K.
  • Los Angeles Capital Management first reported a position in DiaMedica Therapeutics in Q4 2025 and held it in 1 quarter.
  • Los Angeles Capital Management's DiaMedica Therapeutics position peaked at $161K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.